NEVRO CORP's ticker is NVRO and the CUSIP is 64157F103. A total of 197 filers reported holding NEVRO CORP in Q3 2021. The put-call ratio across all filers is 2.17 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $460,102 | -46.8% | 18,100 | -24.4% | 0.00% | -50.0% |
| Q1 2023 | $864,924 | +25.4% | 23,926 | +37.4% | 0.01% | +33.3% |
| Q4 2022 | $689,476 | -80.6% | 17,411 | -18.8% | 0.01% | -84.2% |
| Q2 2021 | $3,556,000 | +612.6% | 21,449 | +329.8% | 0.04% | +22.6% |
| Q1 2020 | $499,000 | +101.2% | 4,991 | +135.9% | 0.03% | +416.7% |
| Q4 2019 | $248,000 | -28.7% | 2,116 | -65.3% | 0.01% | -60.0% |
| Q3 2018 | $348,000 | -12.8% | 6,100 | +22.0% | 0.02% | -31.8% |
| Q2 2018 | $399,000 | -77.0% | 5,000 | -75.0% | 0.02% | -83.1% |
| Q1 2018 | $1,734,000 | -46.0% | 20,008 | -57.0% | 0.13% | -50.6% |
| Q4 2017 | $3,214,000 | +892.0% | 46,555 | +1207.7% | 0.26% | +776.7% |
| Q3 2017 | $324,000 | -79.2% | 3,560 | -83.0% | 0.03% | -81.2% |
| Q2 2017 | $1,556,000 | -53.5% | 20,906 | -54.6% | 0.16% | -63.0% |
| Q4 2016 | $3,345,000 | +1335.6% | 46,033 | +1966.1% | 0.43% | +982.5% |
| Q3 2016 | $233,000 | -38.7% | 2,228 | -67.0% | 0.04% | -74.2% |
| Q1 2016 | $380,000 | – | 6,742 | – | 0.16% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Iron Triangle Partners LP | 562,833 | $40,710,000 | 4.84% |
| Altium Capital Management LP | 77,000 | $5,569,000 | 1.86% |
| PFM Health Sciences, LP | 649,513 | $46,979,000 | 1.76% |
| Rock Springs Capital Management LP | 721,500 | $52,186,000 | 1.31% |
| Integral Health Asset Management, LLC | 50,000 | $3,617,000 | 0.94% |
| Redmile Group, LLC | 411,017 | $29,729,000 | 0.93% |
| K2 PRINCIPAL FUND, L.P. | 114,800 | $8,303,000 | 0.72% |
| Connacht Asset Management LP | 18,762 | $1,357,000 | 0.70% |
| Perceptive Advisors | 477,037 | $34,504,000 | 0.69% |
| ArrowMark Colorado Holdings LLC | 855,439 | $61,874,000 | 0.54% |